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Abstract
Background: The hTERT (human telomerase reverse transcriptase) gene contains five variable number tandem
repeats (VNTR) and previous studies have described polymorphisms for hTERT-VNTR2-2
nd. We investigated how
allelic variation in hTERT-VNTR2-2
nd may affect susceptibility to prostate cancer.
Methods: A case-control study was performed using DNA from 421 cancer-free male controls and 329 patients
with prostate cancer. In addition, to determine whether the VNTR polymorphisms have a functional consequence,
we examined the transcriptional levels of a reporter gene linked to these VNTRs and driven by the hTERT promoter
in cell lines.
Results: Three new rare alleles were detected from this study, two of which were identified only in cancer
subjects. A statistically significant association between rare hTERT-VNTR2-2
nd alleles and risk of prostate cancer was
observed [OR, 5.17; 95% confidence interval (CI), 1.09-24.43; P = 0.021]. Furthermore, the results indicated that these
VNTRs inserted in the enhancer region could influence the expression of hTERT in prostate cancer cell lines.
Conclusions: This is the first study to report that rare hTERT VNTRs are associated with prostate cancer
predisposition and that the VNTRs can induce enhanced levels of hTERT promoter activity in prostate cancer cell
lines. Thus, the hTERT-VNTR2-2
nd locus may function as a modifier of prostate cancer risk by affecting gene
expression.
Background
Telomeres play a critical role in the maintenance of
genomic stability in all eukaryotes [1]. Telomerase, a
ribonucleoprotein complex with RNA template and cat-
alytic subunit hTERT core components, is able to add
reiterated telomeric repeat sequences to the very ends of
chromosomes. While the telomerase RNA template is
present in almost all human cells, hTERT was found to
be rate limiting for telomerase activity [2,3]. Telomerase
expression is confined primarily to the germ line and
regenerating tissues in adults [3,4]. Activation of telo-
merase to maintain telomeres is required for self-
renewal and proliferative expansion of a number of cell
types, including stem cells, activated lymphocytes and
cancerous cells [2,3,5]. Human telomerase is highly
active in more than 85% of primary cancers, but not in
most differentiated somatic tissues. Ectopic expression
of hTERT in otherwise mortal human cells induces effi-
cient elongation of telomeres and permanent cell growth
[2,3,5].
In our previous work, we described the isolation and
characterization of the complete genomic human telo-
merase gene [6]. The hTERT gene contains four blocks
of polymorphic minisatellite regions: two blocks of
V N T R sw i t h i ni n t r o n2( V N T R 2 - 1
st and VNTR2-2
nd)
and two within intron 6 (VNTR6-1
st and VNTR6-2
nd)
[6,7]. In a previous study, we found that hTERT-
VNTR2-2
nd contains minisatellites with 61-bp periodi-
city. We identified four alleles of hTERT-VNTR2-2
nd
ranging from 40 to 44 copies of the 61-bp repeat unit,
with 44 the most common, and a corresponding degree
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approximately 10%. Analysis of segregation of the minis-
atellites in families revealed that all four VNTR alleles
are transmitted in a Mendelian inheritance pattern [6].
Despite the lack of understanding about the function
of repetitive DNA, these elements have been implicated
in the pathogenesis of human genetic disease [8-11].
VNTR polymorphisms have also been reported to affect
gene expression [12,13]. The high level of VNTR poly-
morphism and consequent heterozygosity pose a pro-
blem as to what haplotypes are present in a given cell
and which of them is responsible for gene expression.
Comparison of normal and cancer tissue from patients
revealed rearrangements of at least two VNTR regions
of hTERT, suggesting that the minisatellites might be
associated with activation of telomerase expression in
cancer cells [6]. Many repeats of hTERT-VNTR2-1
st
include the canonical CACGTG binding site of the
MYC family of oncogenic transcription factors, that is
also present in the promoter region; overexpression of
c-MYC activates hTERT transcription through this pro-
moter element [6,14].
In this study, we investigated how allelic variation in
hTERT-VNTR2-2
nd affects susceptibility to sporadic
cancers of the prostate. A case-control study using a
PCR-based method was performed to compare the alle-
lic distribution of hTERT-VNTR2-2
nd in DNA samples
from cancer-free controls and patients with cancer. We
identified three novel minisatellite alleles in the hTERT-
VNTR2-2
nd r e g i o n .F u r t h e r m o r e ,t od e t e r m i n ei ft h e
VNTR polymorphisms are functional, we examined the
transcriptional levels of a hTERT promoter-driven
reporter gene in the presence of VNTRs with a varying
number of repeats in prostate cancer cell lines. Our
results indicate that allelic variations in the minisatellites
of hTERT-VNTR2-2
nd may be related to susceptibility to
prostate cancer by affecting the expression level of
hTERT in cancer cell lines.
Methods
Study population
The degree of minisatellite polymorphism in hTERT-
VNTR2-2
nd was assessed in 421 unrelated healthy adult
males. In addition, we performed a case-control study in
which we compared DNA from these 421 cancer-free
controls to samples obtained from 329 patients with
prostate cancer. Controls were selected from the
Department of Preventive Medicine and Internal Medi-
cine of Dong-A University hospitals between 2000 and
2004 (Busan, Korea). A total of 421 male individuals in
the control group who had no personal history of can-
cers or current cancer were recruited and completed an
interview. The controls had a similar age distribution to
the cancer patients (control mean age, 66.7 y, range 50-
89 y; patients mean age, 67.9 y, range 50-88 y). Subjects
were recruited from five different hospitals in four dif-
ferent cities in Korea: Dong-A University Hospital and
Busan Paik Hospital in Busan, Chungbuk National Uni-
versity Hospital in Cheongju, Asan Medical Center in
Seoul, and Ulsan University Hospital in Ulsan. Prior to
collection, each participating subject provided his
informed consent. The Committees of Bioethics of
Dong-A University [#IRB-06-10-02 & IRB-07-10-7;
Busan, Korea] and Chungbuk National University Hos-
pital [#IRB-2006-1; Cheongju, Korea] approved the
study design and procedures.
PCR analysis of hTERT-VNTR2-2
nd
To assess the degree of polymorphism of hTERT-VNTR2-
2
nd, we analyzed genomic DNA samples from 329 prostate
cancer patients and 421 healthy, unrelated adult males. For
PCR experiments, genomic DNA from peripheral blood
lymphocytes was extracted as described [10]. Primer
sequences used in this study are as follows: hTERT-
VNTR2-2
nd F-TGGGAGCATCACTCACAGGA and
hTERT-VNTR2-2
nd R-GGAACACAGCCAACCCCTTA
[6]. PCR analysis of human DNA samples was performed
using the Promega Go Taq polymerase (Promega, WI)
with 100 ng genomic DNA. Genomic DNA was amplified
using primers under the following standard PCR condi-
tions: 50 mM KCl; 10 mM Tris-HCl, pH 9.0; 3 mM
MgCl2; and 0.2 mM dTTP, dCTP, dGTP, and dATP in a
final volume of 40 μl. PCR was conducted in a 9700 Ther-
malcycler (Perkin-Elmer, CA, USA) with cycle conditions
consisting of 94°C for 2 min, 30 cycles of 45 sec at 94°C
and 69°C for 2 min 30 sec. The last elongation step was
extended to 7 min at 72°C. PCR products were analyzed
by gel electrophoresis (1 volt/cm) in TAE buffer through
0.8% agarose gel.
Three newly identified hTERT-VNTR2-2
nd alleles were
amplified from human genomic DNA using a PCR
method for sequencing (Figure 1). After electrophoresis,
the PCR products were extracted using a gel extraction
kit (Qiagen, CA), and the repeat sequence of the PCR
product was analyzed.
Plasmid construction
Af r a g m e n to ft h ehTERT promoter (-304 to +40) [15]
was amplified from a bacterial artificial chromosome
clone containing the hTERT g e n o m i cs e q u e n c e[ 6 ]a n d
inserted into KpnI/NheI sites of the luciferase reporter
vector pGL3-Basic (Promega) to generate the pBT304
construct (Figure 2-A). Two common alleles (TR42,
TR44) and three rare alleles (TR28, TR37, TR39) were
amplified from genomic DNA from patients with pros-
tate cancer (Figure 1-B) and inserted into the BglII/SalI
sites of pBT304 to make the reporter plasmids pBT304
+TR28, pBT304+TR37, pBT304+TR39, pBT304+TR42,
Yoon et al. BMC Cancer 2010, 10:393
http://www.biomedcentral.com/1471-2407/10/393
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mids containing TR were also constructed in the reverse
orientation in the reporter to examine the effect of TR
orientation on gene expression. Moreover, to compare
the effect of similarly sized irrelevant DNA sequences
on luciferase expression, the pBT304+2443 plasmid was
made by insertion of a 2443-bp fragment (UCSC,
>hg18_dna; Chr5: 4359328-4361770) into the BglII/SalI
sites instead of TR. All constructs were confirmed by
DNA sequencing.
Cells and luciferase assay
The following human cell lines were examined for the
effect of VNTRs on hTERT expression: 293T/HEK293T
(human embryonic kidney cell line obtained from the
Korean Cell Line Bank (KCLB), South Korea), RWPE-1
(prostate cell line obtained from the American Type
Culture Collection (ATCC), USA), PC-3 (prostate can-
cer cell line obtained from KCLB), and LNCap (prostate
cancer cell line obtained from KCLB). For the luciferase
assay, cells (1 × 10
5) were seeded in 12-well plates, cul-
tured overnight, and transfected with the hTERT pro-
moter-luciferase plasmids (0.5 μg per well) by using the
FuGENE6 transfection reagent (Roche Diagnostics,
USA) at a ratio of DNA to FuGENE6 of 1:3. The cells
were analyzed using a dual-luciferase reporter assay sys-
tem (Promega) 48 h after completion of the transfection
procedure. Firefly luciferase activity was normalized
according to Renilla luciferase activity and expressed as
relative luciferase units to reflect promoter activity. Tri-
plicate transfections of each construct were examined
for each experiment, and final results were calculated
from four independent experiments.
Statistical Analysis
The degree of polymorphism, which ranges from 0 to 1,
generally increases with the number of alleles. To evalu-
ate the probability of two randomly chosen alleles being
different (heterozygosity) at a given locus, a measure of
genetic diversity was calculated using the method
described by Chakravarti and Lynn [16]. Regression ana-
lyses were performed to determine the odds ratios
(ORs) of associations between control and patient
groups. ORs were estimated using the natural logarithm
and its standard error. Where relevant, we used a chi-
squared test with one degree of freedom to assess statis-
tical significance. Differences were considered significant
for confidence intervals (CIs) of 95%. All tests were two-
sided, with P < 0.05 considered statistically significant.
Statistical analyses were performed using MS Excel with
CHITEST and R statistical software (v2.5.1, http://www.
r-project.org) with chisq.test for the calculation of chi-
squared values.
Results
Three new rare alleles at hTERT-VNTR2-2
nd
In this study, we analyzed the degree of polymorphism
within the hTERT-VNTR2-2
nd repeats by PCR amplifi-
cation of human genomic DNA samples isolated from
421 cancer-free males and 329 prostate cancer patients
(Figure 1). We assessed the degree of heterozygosity in
each sample group according to allelic distribution. The
heterozygosity of hTERT-VNTR2-2
nd was 0.4782 in con-
trols and 0.4964 in prostate cancer patients, with no sta-
tistically significant difference between the two groups.
We identified 5 alleles in 421 control samples ranging
from 39 to 44 copies of the 61-bp repeat unit, with 44
copies present in the most common allele (Table 1).
Compared to a previous report [6], we observed one
novel allele, with 39 copies of the 61-bp repeat unit, in
the control group (Figure 1-A). We also observed two
additional novel alleles, of 28 and 37 copies, in the pros-
tate cancer group (Figure 1-B). Thus, three new alleles
were identified at the hTERT-VNTR2-2
nd locus in this
study: one in controls and two cancer-specific alleles in
prostate cancer patients (Table 1). The genotype distri-
bution of hTERT-VNTR2-2
nd variants in prostate cancer
Figure 1 Allele typing at hTERT-VNTR2-2
nd in cancer-free
controls and patients with prostate cancer. (A) Electrophoretic
patterns of PCR products of hTERT-VNTR2-2
nd in controls. Four
hTERT-VNTR2-2
nd alleles and six haplotype patterns were detected in
DNA from 421 cancer-free male controls. One new rare allele (39
copies of the repeat unit) and one previously reported rare allele
(40 copies) identified in the control group are indicated with arrows.
(B) Electrophoretic patterns of PCR products of hTERT-VNTR2-2
nd in
patients with prostate cancer. Seven hTERT-VNTR2-2
nd alleles and
eleven haplotype patterns were detected in DNA from 329 patients
with prostate cancer. The three new rare alleles (28, 37, and 39
copies) and one previously reported rare allele (40 copies) identified
in prostate patients are indicated with arrows. The 28- and 37-copy
alleles were detected only in patients with prostate cancer. The first
and last lanes correspond to a 1-kb marker (M).
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Page 3 of 10Figure 2 Effect of allelic types of hTERT-VNTR2-2
nd in hTERT-promoter luciferase constructs. (A) The structure of the pBT304 (#1) and TR
reporter constructs. The gray square indicates the hTERT promoter region. The open square represents the open reading frame of luciferase. The
black squares include the VNTR polymorphic regions of hTERT-VNTR2-2
nd. Five different sizes of TR (28-44 copies) were inserted in the pBT304
plasmid: pBT304 + TR28, pBT304 + TR37, pBT304 + TR39, pBT304 + TR42, and pBT304 + TR44 (#2-6). All TR-containing plasmids were constructed
in both the forward and reverse directions of the reporter gene. The pBT304+2443 plasmid (#7) was made by insertion of an irrelevant 2443-bp
fragment instead of TR. (B) The effects of VNTR polymorphism on hTERT gene expression in the luciferase reporter system. Four different cell
lines (293T, embryonic kidney, RWPE-1, prostate, LNCap and PC-3, prostate cancer) were transfected with 12 different plasmids [#1-7, with paired
forward- and reverse-TR-containing constructs (#2-6)]. * denotes statistical significance (P < 0.05).
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ven patterns were identified in prostate cancer patients;
only six patterns were observed in controls (Figures 1-A
and 1-B). Five rare cancer-specific genotypes were iden-
tified in patients with prostate cancer (28/44, 37/44, 39/
44, 40/42 and 40/44) (Figure 1-B and Table 2).
Association of rare hTERT-VNTR2-2
nd alleles with prostate
cancer
For further analysis, hTERT-VNTR2-2
nd alleles were
grouped into two sets (common and rare alleles),
according to their frequency in the control population.
The expected frequency for rare alleles was considered
≤1% in this study. Analysis of the genotypes found in
individual cancer patients and healthy controls revealed
that having a rare allele (2.43% of patients, 0.48% of
controls) was associated with relative prostate cancer
odds of 5.22 (CI: 1.10-24.76; P = 0.02) (Table 2).
Furthermore, the repeat sizes of all rare alleles (28, 37,
39 and 40 copies) were shorter than common alleles
(42, 43, and 44 copies). Therefore, there is a statistically
significant risk for developing prostate cancer associated
with the presence of shorter, rare alleles. Table 3 sum-
marizes the frequency of rare and common hTERT-
VNTR2-2
nd alleles (haplotype) among cancer patients
and controls. Interestingly, in patients with prostate can-
cer, the total rate of rare hTERT-VNTR2-2
nd alleles was
1.22%, compared to 0.24% in cancer-free male controls.
Analysis of these data revealed a statistically significant
association between rare hTERT-VNTR2-2
nd alleles and
risk of prostate cancer (OR, 5.17; 95% CI, 1.09-24.43;
P = 0.021) (Table 3).
We further analyzed the hTERT-VNTR2-2
nd allele
types on the basis of subject age. Table 4 shows the gen-
otype distribution in patients according to age at diag-
nosis and in controls according to age at the time of
study enrollment. In the control group, we found that
there was no difference in the frequencies of short rare
alleles between younger (<65 years) and older (≥65
years) individuals (P =0 . 2 1 ) .I nc o m p a r i s o nt oo l d e r
patients (≥65 years), however, we found that younger
patients (<65 years) had an increased ratio (3.79, CI:
0.89-16.18; P = 0.05) of association between rare
hTERT-VNTR2-2
nd alleles and prostate cancer. The fre-
quency of rare alleles was higher in younger cases
(4.9%) than in older cases (1.3%). Specifically, a compari-
son between controls and cancer patients by age group
demonstrated a statistically significant difference (P =
0.02) in the association ratio between prostate cancer
and rare hTERT-VNTR2-2
nd alleles in younger patients
(Table 4).
We used additional clinicopathological information
collected from 2005-2006 at the Asan Medical Center in
Korea [17,18] and in 2006 at the National Cancer Cen-
ter in Korea [19] (Table 5) to further characterize pros-
tate cancer patients. Tumor, node, and metastases
(TNM) stage and histopathological classifications were
analyzed according to the World Health Organization
(WHO) system. Prostate cancer was evaluated using
TNM stage, Gleason score, prostate-specific antigen
(PSA), Jewett-Whitmore system, and the Tumor grade
(Table 5). Prostate tumors were grouped according to
their classification, and we then estimated the frequency
of each stage in the total cancer group and in the rare
allele group by Pearson’s chi-squared test (Table 5).
We determined the proportion of TNM stages within
the short rare alleles group and the prostate cancer
group. The frequency of short rare allele patients in the
T4 stage was slightly higher than in the total prostate
cancer group (P = 0.1110), and the frequency of short
rare allele patients in the N1 and M1 stages was signifi-
cantly higher than in the total prostate cancer group
(P =0 . 0 1 4 6a n dP = 0.0422, respectively). We then
Table 1 Haploid types of hTERT-VNTR2-2
nd in male
controls and patients with prostate cancer
Haplotype Male
controls
Prostate
cancer
OR (95% CI) P
TR Size
(bp)
842 [N(%)] 658 [N(%)]
28 1934 - 1 (0.0015) - 0.258
37 2483 - 1 (0.0015) 0.258
39 2605 1 (0.0012) 4 (0.0061) 5.14 (0.57-46.13) 0.103
40 2666 1 (0.0012) 2 (0.0030) 2.56 (0.23-28.34) 0.426
42 2788 307 (0.3646) 232 (0.3526) 0.95 (0.77-1.17) 0.630
43 2849 21 (0.0249) 13 (0.0198) 0.79 (0.39-1.59) 0.503
44 2910 512 (0.6081) 405 (0.6155) 1.03 (0.84-1.27) 0.770
Table 2 Allelic genotypes and frequency in male controls
and cases
Genotype Male controls
421 [N(%)]
Prostate cancer
329 [N(%)]
OR (95% CI) P
28/44 0 (0.00) 1 (0.30) - 0.2576
37/44 0 (0.00) 1 (0.30) - 0.2576
39/42 1 (0.24) 1 (0.30) 1.28 (0.08-20.5) 0.8611
39/44 0 (0.00) 3 (0.91) - 0.0496*
40/42 0 (0.00) 1 (0.30) - 0.2576
40/44 1 (0.24) 1 (0.30) 1.28 (0.08-20.5) 0.8611
42/42 54 (12.83) 37 (11.25) 0.86 (0.55-1.34) 0.5107
42/43 6 (1.43) 6 (1.82) 1.28 (0.41-4.02) 0.6660
42/44 192 (45.61) 150 (45.59) 1.00 (0.75-1.34) 0.9972
43/44 15 (3.56) 7 (2.13) 0.59 (0.24-1.46) 0.2477
44/44 152 (36.10) 121 (36.79) 1.03 (.076-1.39) 0.8491
C/C 419 (99.52) 321 (97.57) 5.22 (1.10-24.76)
C/R 2 (0.48) 8 (2.43) P = 0.02*
Bold numbers represent the rare alleles of hTERT-VNTR2-2
nd. C, common
alleles; R, rare alleles. * Statistically significant (P < 0.05)
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biomarker for detecting prostate cancer [20], to deter-
mine the relationship between PSA level and short rare
alleles in the prostate cancer group. Although three of
the eight patients with rare alleles showed high levels of
PSA (>20 ng/ml), no statistically significant differences
were observed due to the small group size. According to
the Jewett-Whitmore system, prostate cancer is classi-
fied according to anatomical view and spread. A and B
are early stages; stage C and D cancer invades most of
the prostate and spreads to other organs/tissues [21]. In
the present study, 10.7% of patients were classified as
group A, 38.4% as group B, 20.4% as group C, and
30.5% as group D. Prostate cancer patients with rare
alleles were distributed as follows: A (0%), B (12.5%), C
(12.5%), and D (75%). The frequency of patients with a
rare allele in the ‘D’ group was higher than in the total
prostate cancer group, but, as with T4 staging and PSA
level, no statistically significant difference was observed
(P = 0.0605) in the Jewett-Whitmore system.
Effect of VNTR polymorphisms on hTERT expression
To determine if VNTR polymorphisms affect hTERT
expression levels, we constructed reporter vectors that
contained the hTERT promoter, luciferase gene, and one
of five differently sized VNTR repeats ranging from 28
to 44 copies of the 61-bp tandem repeat region of
hTERT-VNTR2-2
nd (PCR product sizes: approximately
1,930-2,900 bp) inserted in the enhancer region of the
pGL3-Basic vector (Figure 2-A). The effects of these
VNTRs in cell lines were examined by transfection of
the luciferase plasmid pBT304 with or without each
VNTR repeat variant. In 293T (human embryonic
kidney cell line) and RWPE-1 (human prostate cell line)
cells, no statistically significant differences in luciferase
activity were observed between controls (pBT304 and
pBT304 + 2443) and VNTR-containing cells (pBT304 +
TR, with both orientations of five different TRs) (Figure
2-B). Interestingly, when we transfected these plasmids
into two different prostate cancer cell lines (PC3 and
LNCap cells), luciferase assays revealed that forward-
VNTRs stimulated the activity of the hTERT promoter,
leading to approximately 1.4 to 1.9-fold increases in
relative luciferase activity in LNCap cells and 2.5 to 3.7-
fold increases in PC3 cells (Figure 2-B). Notably, the
PC3 cell line demonstrated a greater increase in lucifer-
ase activity as compared to the LNCap cell line. How-
ever, when we recalculated relative luciferase activity by
comparing the forward- and reverse-VNTRs of each var-
iant, the increase in luciferase activity was similar in
both cell lines, ranging from 1.4 to 1.7-fold in LNCap
cells and 1.7 to 1.9-fold in PC3 cells. Similarly sized irre-
levant DNA sequences (pBT304 + 2443) had no effect
on luciferase expression.
Discussion
A characteristic of tandem repetitive sequences is their
ability to give rise to variants that contain increased or
decreased numbers of the repeat unit. A recent study of
genetic factors involved in susceptibility to insulin-depen-
dent diabetes mellitus demonstrates the importance of
population-based association studies in understanding
the effects of VNTRs [22]. Some minisatellite alleles are
associated with human disorders and with differential
expression of a nearby gene [23], which lends support to
the concept that variations in a minisatellite locus may
Table 3 The rare hTERT -VNTR2-2
nd alleles associated with prostate cancer
Samples No. of alleles Common alleles Rare alleles OR (95% CI) P
42 43 44 Total 28 37 39 40 Total
Male
controls
842
(%)
307
(36.46)
21
(2.49)
512
(60.81)
840
(99.76)
0011 2
(0.24)
1 (reference) -
Prostate
Cancer
658
(%)
232
(35.26)
13
(1.97)
405
(61.55)
650
(98.78)
1142 8
(1.22)
5.17
(1.09-24.43)
0.021*
* Statistically significant (P < 0.05)
Table 4 Frequency of hTERT-VNTR2-2
nd and risk of prostate cancer by age
Male controls Prostate cancer cases OR (95% CI); P
Age at diagnosis Total cases Rare alleles Total cases Rare alleles Reference
(Controls of the same age)
Younger
(<65 years)
185 0 (0%) 103 5 (4.9%) ND; P = 0.002*
Older
(≥65 years)
236 2 (0.9%) 226 3 (1.3%) 1.57 (0.26-9.46); P = 0.62
Reference
(Older group)
ND; P = 0.21 3.79 (0.89-16.03); P = 0.05
* Statistically significant (P < 0.05)
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implicated rare HRAS minisatellite alleles in cancer risk
[24,25], and specific HRAS minisatellite alleles have
demonstrated enhancer or suppressor activity in vitro [26].
VNTRs in introns may also affect mRNA splicing [27]. In
addition, rare VNTR alleles have been associated with a
higher risk of various types of cancer [10,23,28]. These
findings suggest a potential biological role for rare minisa-
tellite alleles in cancer predisposition; however, the nature
of the phenomena underlying the association between
minisatellites and cancer has remained unclear.
Telomerase activity is detected in approximately 85%
of malignant tumor cells, and its presence can be used
to diagnose cancer [29]. Regulation of the hTERT gene
is a major factor in telomerase activity [30], and the
expression level of hTERT is highly correlated with telo-
merase activity in normal and cancer cells [31]. hTERT
includes four polymorphic minisatellites, 42- and 61-bp
minisatellites in intron 2 (VNTR2-1
st and 2-2
nd)a n d
38- and 36-bp minisatellites in intron 6 (VNTR6-1
st and
6-2
nd), as well as an apparently monomorphic 28-bp
minisatellite in intron 12 (TR12) [6]. The influence of
these minisatellites on gene expression is not known,
but they may intervene in regulatory mechanisms affect-
ing hTERT expression. The DNA from cancer tissues of
one patient with a kidney tumor had a simultaneous
rearrangement of hTERT-VNTR6-1
st and 6-2
nd [6,7], an
observation that suggests that chromosomal rearrange-
ments involving these VNTRs may be associated with
the activation of telomerase expression in cancer. More-
over, according to reports by Wang et al.[ 2 3 ] ,
MNS16A, which is located downstream of hTERT,w a s
reported to have an effect on hTERT expression and tel-
omerase activity. In a previous study, we characterized
hTERT-VNTR2-2
nd as having four alleles containing a
different number of the repeat unit in 103 normal,
Table 5 Tumor characteristics in cases with total cases and rare alleles
Characteristic 2006
AMC*
2006
NCC**
2005
AMC*
This study Rare alleles c
2-value***
(P value)
Age
Mean 63.9 (42-78) 64.1 (46-80) 64.3 (40-83) 67.9 (50-88) 64.7 (55-81)
T-stage
T1 0 (0.0%) 0 (0.0%) 130 (41.0%) 42 (13.2%) 0 (0.0%) 6.0132 (df = 3)
T2 116 (62.4%) 52 (63.4%) 183 (57.7%) 139 (43.8%) 3 (42.9%) P = 0.1110
T3 68 (36.6%) 29 (35.4%) 4 (1.3%) 95 (30.0%) 1 (14.3%)
T4 2 (1.1%) 1 (1.2%) 0 (0.0%) 41 (12.9%) 3 (42.9%)
N-stage
N0 182 (97.8%) 45 (91.8%) 291 (91.8%) 265 (85.8%) 3 (42.9%) 6.7334 (df = 1)
N1 4 (2.2%) 4 (8.2%) 26 (8.2%) 44 (14.2%) 4 (57.1%) P = 0.0095
M-stage
M0 158 (84.9%) 45 (91.8%) 280 (88.3%) 247 (75.5%) 3 (37.5%) 4.1265 (df = 1)
M1 28 (15.1%) 4 (8.2%) 37 (11.7%) 80 (24.5%) 5 (62.5%) P = 0.0422
Gleason score
2-6 34 (18.3%) 22 (31.9%) 126 (39.8%) 71 (23.5%) 1 (12.5%) 2.839 (df = 2)
7 108 (58.0%) 33 (47.8%) 98 (30.9%) 95 (31.5%) 1 (12.5%) P = 0.2418
8-10 44 (23.7%) 14 (20.3%) 93 (29.3%) 136 (45.0%) 6 (75.0%)
PSA (ng/ml)
<10 110 (59.1%) 41 (49.4%) 142 (44.8%) 29 (34.1%) 0 (0.0%) 2.253 (df = 2)
10-20 57 (30.7%) 21 (25.3%) 102 (32.2%) 8 (9.4%) 0 (0.0%) P = 0.3241
>20 19 (10.2%) 21 (25.3%) 73 (23.0%) 48 (56.5%) 3 (100%)
Jewett-Whitmore system
A 35 (10.7%) 0 (0.0%) 7.3884 (df = 3)
B ND ND ND 126 (38.4%) 1 (12.5%) P = 0.0605
C 67 (20.4%) 1 (12.5%)
D 100 (30.5%) 6 (75.0%)
Tumor grade
Well 25 (7.9%) 9 (3.0%) 0 (0.0%) 0.6087 (df = 2)
Moderate ND ND 101 (31.9%) 62 (20.5%) 1 (12.5%) P = 0.7376
Poor 191 (60.3%) 231 (76.5%) 7 (87.5%)
*Data of Asan Medical Center, Korea; ** Data of National Cancer Center, Korea; *** Pearson’s Chi-squared test was performed between total cases with prostate
cancer and cases with rare alleles used in this study.
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that hTERT-VNTR2-2
nd regulated hTERT promoter
activity in a reporter gene assay.
We hypothesized that hTERT-VNTR2-2
nd polymorph-
isms could play a role in activating hTERT during
tumorigenesis. The present case-control study was per-
formed on DNA from 421 cancer-free male controls
and patients with 329 prostate cancers using PCR meth-
ods to determine the frequency of rare alleles. These
data suggest a statistically significant (P =0 . 0 2 1 )
increased incidence of rare hTERT-VNTR2-2
nd alleles in
prostate cancer patients (1.22%) compared to male con-
trols (0.24%). Moreover, the frequency of rare alleles
among prostate cancer patients was significantly higher
in younger patients (4.9%) than in older patients (1.3%)
(P = 0.02). These results suggest that rare hTERT-
VNTR2-2
nd alleles may be genetically associated with
prostate cancer.
Prostate cancer is often diagnosed at an advanced
stage, and metastatic prostate cancer is incurable.
Although the advent of the PSA test and increased pub-
lic awareness have improved early detection rates, a
large number of patients still die of metastatic prostate
cancer, reflecting the presence of occult metastatic dis-
ease [32]. The diagnosis of early-stage prostate cancer is
imperative for its successful treatment, but the methods
employed in diagnosis suffer from significant limitations.
H e r e ,w ef o u n dad i f f e r e n tproportion of TNM stages
between the short rare-allele group and the prostate
cancer group as a whole. Prostate cancer tissue classified
as M1-stage, N1-stage, or Jewett-Whitmore group ‘D’ is
associated with a poor prognosis. Using the Jewett-
Whitmore system, the frequency of cases with a rare
allele in the ‘D’ group was higher than in the total pros-
tate cancer group, but no statistically significant differ-
ence was observed due to the limited number of
samples. However, there were significant relationships
between the short rare allele and the appearance of
regional lymph nodes (N1 stage) and metastasis (M1
stage). These results suggest that prostate cancer
patients with rare hTERT-VNTR2-2
nd alleles have a
poorer prognosis than patients with common alleles.
This study is the first to calculate the risk of prostate
cancer attributable to rare hTERT-VNTR2-2
nd alleles and
report that rare hTERT-VNTR2-2
nd alleles of the human
telomerase gene contribute to prostate cancer predisposi-
tion in the general population. This finding may prove
useful as a diagnostic biomarker of increased risk for
prostate cancer and cancer progression, though the short
rare alleles group is too small to be common in prostate
cancer cases. Further research is necessary to identify the
specific minisatellite variants that confer predisposition
and to further evaluate the associations between hTERT-
VNTR2-2
nd alleles and cancers of the prostate.
Sequence analyses highlighted possible mechanisms
underlying the relationship we observed between
hTERT-VNTR2-2
nd alleles and prostate cancer. When
the minisatellite sequences were analyzed using the
Transfac software (MATCH™ public version 1.0; http://
www.gene-regulation.com/pub/databases.html), we
f o u n df i v ep u t a t i v eb i n d i n gs i t e sf o rt h et r a n s c r i p t i o n
factor, estrogen receptor 1 (ER1), in the repeat region of
hTERT-VNTR2-2
nd. The estrogen receptor a subunit is
expressed in androgen receptor-dependent prostate can-
cer, suggesting that the ER pathway may be involved in
prostate cancer. We also found binding sites in repeat
regions for the transcription factors v-ErbA (5 sites) and
NF-kappaB (3 sites), which are related to cancer devel-
opment [33-35]. However, these latter sites were found
by scanning all of the putative regulatory elements (min-
isatellites, etc.), including those in introns. In a report by
Brandt et al. [36], a transcriptional regulation mechan-
ism has been described that depends on the length of a
CA repeat in intron 1 (CA simple sequence repeat 1) of
the EGFR gene. This mechanism may also be involved
in regulation of the hTERT gene, with oncogenic pro-
teins binding to sites in repeat regions and stimulating
hTERT expression during cancer progression.
On the basis of these putative binding sites, we investi-
gated the effects of VNTR polymorphism on hTERT
gene expression in cell lines by using the luciferase repor-
ter system to observe the effect of VNTRs on the hTERT
promoter. In PC3 and LNCap prostate cancer cell lines,
all five VNTR constructs enhanced the activity of the
hTERT promoter, but with no clear relationship between
the number of repeats and the change in expression. This
finding may be indicative of the limitations of in vivo
transient transcriptional regulation assays. Alternatively,
the high density of putative binding sites within the
repeat array for transcription factors such as ER, v-ErbA
and NF-kappaB may enhance hTERT gene expression
independently of the number of tandem repeats. When
we examined the luciferase activity of the hTERT promo-
ter that included the VNTRs in gastric cancer, no
increase was detected (data not shown). Therefore, the
high density of putative binding sites within the repeat
array for transcription factors such as ER may enhance
hTERT gene expression with cell line specificity.
Conclusions
Our findings suggest that non-coding regions such as
minisatellite repeat regions may influence gene activity.
Further investigations of the epidemiological associa-
tions between minisatellites and cancer, and the role of
repeat regions in gene regulation, are warranted. This
study should also provide a helpful reference for under-
standing the possible function of minisatellites and the
complex genomic properties of genes.
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